May 2nd 2024
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Exploring Novel Agents to Target Pathways in Lymphoma
August 9th 2018Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference.
Watch
POD Within 2 Years of Cytarabine-Containing Treatment Associated With Poor Outcomes in MCL
August 7th 2018Patients with relapsed/refractory mantle cell lymphoma (MCL) who experienced progression of disease within 2 years following an upfront chemoimmunotherapy regimen containing high-dose cytarabine were more likely to have worse outcomes than patients who progressed later, according to the results of a retrospective analysis presented at the 2018 European Hematology Association Congress. Alternatively, patients who experienced POD later had an unexpectedly long life expectancy.
Read More
Ibrutnib in Older Patients With Mantle Cell Lymphoma
August 3rd 2018Brad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.
Watch
Maintenance Rituximab/Bortezomib Demonstrates 90.2% DFS at 2 Years in MCL
July 25th 2018The addition of bortezomib to rituximab as a maintenance therapy following consolidative autologous hematopoietic stem cell transplantation may improve disease-free survival and overall survival in patients with mantle cell lymphoma, results of a small phase II study suggest.
Read More
Ibrutinib/Rituximab Combo Induces 3-Year OS of 69% in Relapsed/Refractory MCL
July 19th 2018The combination of ibrutinib (Imbruvica) and rituximab (Rituxan) produced durable remissions in patients with relapsed/refractory mantle cell lymphoma, according to 4-year follow-up results from a single-arm phase II clinical trial.
Read More
Improved Outcomes Seen With Maintenance Rituximab in MCL
July 19th 2018Maintenance rituximab improved progression-free survival and overall survival following induction chemoimmunotherapy for patients with mantle cell lymphoma, according to results of a recent meta-analysis.<br />
Read More
Mantle Cell Lymphoma Advice for a Community Oncologist
July 18th 2018Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program at Northwell Health Systems, advises community oncologists on how to treat patients with mantle cell lymphoma. She emphasizes the importance of seeking a second opinion for patients that are not responding to treatment.
Watch
Expert Discusses Efficacy of Venetoclax in MCL
June 25th 2018An overall response rate of 60% was induced with venetoclax (Venclexta) monotherapy in patients with poor-risk relapsed/refractory mantle cell lymphoma who were previously treated with a BTK inhibitor, according to results presented at the 2018 European Hematology Association Congress. Of the responding patients, 20% had a complete response.
Read More
PET-Guided De-escalation a Safe, Effective Approach in Advanced Hodgkin Lymphoma
June 22nd 2018In patients with untreated advanced-stage classical Hodgkin lymphoma, PET can be safely used to guide treatment after 2 cycles of upfront de-escalated BEACOPP, according to the final analysis of the phase III LYSA study presented at the 2018 European Hematology Association Congress.
Read More
Novel Assay Identifies Molecular Subtypes in MCL
June 21st 2018The 16-gene Leukemic-MCL16 (L-MCL16) Assay reliably distinguished between classic and indolent mantle cell lymphoma subtypes in patients with leukemic presentation, according to results published in <em>Blood</em>. Combined with genomic complexity, the assay was prognostic for overall survival.
Read More
Wang Discusses Potential for CAR T-Cell Therapy in MCL
June 14th 2018The biggest clinical unmet need in the treatment of patients with mantle cell lymphoma is overcoming resistance to BTK inhibitors, as patients who progress on treatment with ibrutinib (Imbruvica) and acalabrutinib (Calquence) are often incurable, according to Michael Wang, MD. Investigators are now challenged to find a new avenue of treatment.
Read More
Pembrolizumab Approved by FDA for Relapsed/Refractory PMBCL
June 13th 2018Pembrolizumab (Keytruda) has been granted an accelerated approval by the FDA for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or those who have relapsed after 2 or more prior lines of therapy. The approval is based on results from 53 patients with relapsed/refractory PMBCL enrolled in the multicenter, open-label, single-arm KEYNOTE‑170 trial.
Read More
Ibrutinib/Buparlisib Induces Responses in Half of NHL Cohort
June 8th 2018An objective response rate was achieved in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma who received the combination of the BTK inhibitor ibrutinib with the PI3K inhibitor buparlisib, according to findings of a phase I/II trial reported at the 2018 ASCO Annual Meeting.
Read More
Expert from Rutgers Cancer Institute Discusses Ongoing Trials in MCL
May 24th 2018In an interview with <em>Targeted Oncology, </em>Andrew M. Evens, DO, MSc, discusses the clinical trials that are ongoing at Rutgers for patients with mantle cell lymphoma. He shares some details of the current treatment landscape and how that will evolve as more data becomes available from trials like those at his institution.
Read More
Six-Gene Signature Predicts Poor PFS in MCL
May 23rd 2018Expression of genes from the B-cell receptor pathway predicted shorter progression-free survival and overall survival in patients with mantle cell lymphoma, according to results from an examination of a subsection of patients in the ongoing Fondazione Italiana Linfomi MCL-0208 clinical trial.
Read More
Expert Highlights Early Findings for CDK4/6 Inhibition in MCL
May 22nd 2018Palbociclib, a CDK4/6 inhibitor, has demonstrated success against ibrutinib resistance in primary human samples and mantle cell lymphoma cell lines with the mutated BTKC481S protein. Its use has sparked an investigation of combination therapies targeting CDK4 in MCL, said Selina Chen-Kiang, PhD.
Read More
Tisagenlecleucel Granted FDA Approval for Large B-Cell Lymphoma
May 2nd 2018Based on data from the phase II JULIET study, tisagenlecleucel has received FDA approval for the treatment of adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
Read More
Expert Discusses ZUMA-2 Trial Investigating CAR T-Cell Therapy in MCL
April 25th 2018While relapsed/refractory mantle cell lymphoma (MCL) is considered an aggressive disease, new findings show patients may benefit from adding chimeric antigen receptor T-cell therapy to their treatment regimen. ZUMA-2, a currently ongoing trial, aims to understand the potential benefits with axicabtagene ciloleucel, an anti-CD19 CAR T-cell product, for patients with relapsed/refractory MCL.
Read More
Voxtalisib Shows Promising Activity in Follicular Lymphoma
April 24th 2018Voxtalisib (XL765) monotherapy induced objective responses in 41.3% of patients with follicular lymphoma, but displayed minimal efficacy in patients with other lymphomas, according to results from a phase II trial of patients with relapsed or refractory lymphoma or chronic lymphocytic leukemia that were recently published in the Lancet Haematology.
Read More
A Trial Investigating CDK4/6 Inhibitors for the Treatment of Mantle Cell Lymphoma
April 24th 2018Selina Chen-Kiang, PhD, a professor of pathology and immunology at Weill Cornell Medical College, discusses the rationale of her phase I trial investigating the use of CDK4/6 inhibitors for the treatment of patients with mantle cell lymphoma.
Watch
Combinations are the Future for Chemotherapy-Free MCL Treatments
April 23rd 2018The B-Cell Lymphoma Moon Shot Program at The University of Texas MD Anderson Cancer Center wants to increase the cure rate of the disease from 30% to 60% within 5 years. In a presentation at the <em>22nd Annual</em> International Congress on Hematologic Malignancies, Michael Wang, MD, detailed results from 3 clinical trials that may help make that 5-year goal into a reality for patients with mantle cell lymphoma.
Read More
CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma
April 20th 2018Owen O’Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL). This can be tricky for a number of reasons, but O’Connor is hopeful that there are treatment regimens for this patient population that can work.
Watch
Goy Shares Insights on Acalabrutinib and Ibrutinib Data in MCL
April 18th 2018The field of mantle cell lymphoma underwent a significant change with the FDA approval of ibrutinib in 2013. Now, the recent approval of acalabrutinib has similarly impacted the treatment landscape, as experts say it could be associated with slightly fewer adverse events than ibrutinib, according to Andre Goy, MD.
Read More
Combination of Venetoclax and Ibrutinib Shows Promise in MCL
April 9th 2018There was a 16-week complete response rate of 42% per CT imaging with the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in patients with previously untreated or relapsed/refractory mantle cell lymphoma, according to results from the phase II AIM study.
Read More